Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Pharma Ltd.

www.aurobindo.com

Latest From Aurobindo Pharma Ltd.

Indian Firms Take Different Paths On Ranitidine

A double blow to ranitidine medicines  suspension in the EU and a withdrawal request in the US  has caused Indian API and formulation manufacturers to recalibrate their strategies. Amid uncertainty over future prospects for the gastrointestinal drug, Strides is considering a relaunch in the US while Solara is reassigning part of its capacity to manufacture other APIs.

Strategy Generic Drugs

Ranitidine Blow Sees Indian Firms Take Different Paths

A double blow to ranitidine medicines - suspension in the EU and a withdrawal request in the US - has caused Indian API and formulation manufacturers to recalibrate their strategies. Amid uncertainty over future prospects for the gastrointestinal drug, Strides is considering a relaunch in the US while Solara is reassigning part of its capacity to manufacture other APIs.

Commercial Business Strategies

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

Deals Business Strategies

Sandoz Sees Aurobindo Deal Collapse As ‘Opportunity’

Sandoz says closing the door on its proposed deal with Aurobindo will open up opportunities for the Novartis subsidiary to optimize its US business, as global sales for Sandoz shot up by around a tenth in the first quarter of 2020 on the back of a COVID-19 boost and a leap of almost a third in Biopharmaceuticals sales.

Strategy Deals
See All

Company Information

UsernamePublicRestriction

Register